Diko : en:oral aspirin or other antithrombotic therapy prescribed

en:oral aspirin or other antithrombotic therapy prescribed

Catégories

Nom

Informations lexicales

Langue:anglais

Informations sémantiques

source:wiki

Liens externes

›

umls:C3248629

Associations d'idées

[F]

›

438

en:documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:genetic testing for detection of mutations in the presenilin - 1 gene

•

en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia

•

en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:injection, ibuprofen, 100 mg

•

en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy

•

en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function

•

en:injection, belatacept, 1 mg

•

en:injection, aflibercept, 2 mg vial

•

en:injection, alemtuzumab, 1 mg

•

en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater

•

en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge

•

en:injection, epoetin beta, 1 microgram, (for esrd on dialysis)

•

en:patient not treated for motor speech disorder

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis performed

•

en:documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered

•

en:pregnancy test (urine or serum) was not ordered, reason not specified

•

en:injection, dalbavancin, 10 mg administered

•

en:hemodialysis treatment performed less than three times per week or greater than three times per week

•

en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:injection, filgrastim (g-csf), 300 mcg

•

en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing

•

en:netupitant 300 mg and palonosetron 0.5 mg

•

en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:most recent diastolic blood pressure < 90 mmhg

•

en:injection, ferric carboxymaltose, 1 mg

•

en:injection, propofol, 10 mg

•

en:injection, testosterone undecanoate, 1 mg

•

en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel

•

en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery

•

en:most current ldl-c <100mg/dl

•

en:levonorgestrel 52mg intrauterine system

•

en:kras mutation analysis

•

en:intraoperative radiation therapy (single administration)

•

en:injection, zoledronic acid, not otherwise specified, 1mg

•

en:injection, taliglucerase alfa, 10 units

•

en:injection, ramucirumab, 5 mg administered

•

en:injection, ocriplasmin, 0.125 mg

•

en:injection, nivolumab, 1 mg

•

en:injection, blinatumomab, 1 mcg

•

en:injection, interferon beta-1a, 11 mcg for subcutaneous use

•

en:injection, factor viii fc fusion protein(recombinant), per iu

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase

•

en:injection, ado-trastuzumab emtansine, 1 mg

•

en:genetic testing for tay-sachs disease

•

en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record

•

en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:complete gene sequence analysis; msh2 gene

•

en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory

•

en:aneurysm minor diameter <= 5.5 cm for men

•

en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient

•

en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge

•

en:vacuum drainage bottle and tubing for use with implanted catheter

•

en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given

•

en:most recent office visit systolic blood pressure, 130 to 139 mm hg

•

en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given

•

en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given

•

en:score on the reading functional communication measure at discharge was higher than at admission

•

en:score on the memory functional communication measure at discharge was higher than at admission

•

en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given

•

en:patient receiving antiviral treatment for hepatitis c documented

•

en:patient not treated for swallowing disorder

•

en:patient not treated for attention disorder

•

en:patient documentation - angina assessed as present

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month)

•

en:patch closure not used for patient undergoing conventional cea, reason not specified

•

en:serum creatinine test not performed, reason not given

•

en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function

•

en:anoscopy; with directed submucosal injection(s), any substance

•

en:i intend to report the community-acquired pneumonia (cap) measures group

•

en:12-lead electrocardiogram (ecg) not performed, reason not given

•

en:aneurysm minor diameter 5.6-6.0 cm for men

•

en:tissue marker (implantable)

•

en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure

•

en:complete gene sequence analysis; brca1 gene

•

en:fluocinolone acetonide, intravitreal implant

•

en:grafix prime, per square centimeter

•

en:implanted pleural catheter, each

•

en:serum creatinine test result documented and reviewed

•

en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron

•

en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase

•

en:no documentation of disease type, anatomic location, and activity, reason not given

•

en:most recent office visit systolic blood pressure <130 mm hg

•

en:mandibular orthopedic repositioning device, each

•

en:level of activity and symptoms not assessed

•

en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given

•

en:injection, testosterone enanthate, up to 100 mg administered

•

en:injection, pembrolizumab, 1 mg

•

en:epifix, per square centimeter

•

en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg

•

en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family)

•

en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation)

•

en:hemodialysis treatment performed exactly three times per week for > 90 days

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed

•

en:counseling for diet and physical activity performed

•

en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer

•

en:circulating tumor cell test

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)

•

en:aneurysm minor diameter <= 6 cm for men

•

en:type, anatomic location, and activity all documented

•

en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient

•

en:ldl-c was not performed

•

en:aneurysm minor diameter <= 5.5 cm for women

•

en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge

•

en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation

•

en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:patient did not achieve flat retinas six months post surgery

•

en:no documentation of blood pressure measurement, reason not given

•

en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given

•

en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session

•

en:suicide risk not assessed at the initial evaluation, reason not given

•

en:injection, morphine sulfate, 100mg

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed

•

en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)

•

en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)

•

en:female patients with aneurysm minor diameter 5.6-6.0 cm

•

en:counseling for diet and physical activity not performed, reason not given

•

en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression

•

en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:cd4+ cell count or percentage not documented as performed, reason not given

•

en:blood pressure measurement not documented, reason not given

•

en:anti-lipid treatment contraindicated

•

en:injection, isavuconazonium sulfate, 1 mg

•

en:most recent diastolic blood pressure 80 - 89 mm hg

•

en:most recent systolic blood pressure 130 to 139 mm hg

•

en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke

•

en:pregnancy test (urine or serum) ordered

•

en:patient did not have a medical visit in the last 6 months

•

en:patient not treated for memory disorder

•

en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge

•

en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge

•

en:positive airway pressure therapy not prescribed

•

en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function

•

en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg)

•

en:eligible professional does not have prescribing privileges

•

en:ldl value < 100

•

en:injection, siltuximab, 10 mg

•

en:injection, filgrastim (g-csf), 480 mcg

•

en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units

•

en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)

•

en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment)

•

en:documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:complete gene sequence analysis; brca2 gene

•

en:clinician documented that patient was not an eligible candidate for autogenous av fistula

•

en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c

•

en:abdominal aortic aneurysm is not infarenal

•

en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:severity of angina not assessed according to level of activity

•

en:patch closure used for patient undergoing conventional cea

•

en:assessed level of activity and symptoms

•

en:ldl value >= 100

•

en:capsaicin 8% patch, per 10 square centimeters

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

en:urine protein test was not performed, reason not given

•

en:unlisted procedure, intestine

•

en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device

•

en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge

•

en:prostate cancer antigen 3 (pca3) testing

•

en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge

•

en:patient not treated for spoken language comprehension disorder

•

en:most recent office visit systolic blood pressure >=140 mm hg

•

en:most recent ldl-c >= 100 mg/dl

•

en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge

•

en:injection, testosterone cypionate, 1 cc, 200 mg

•

en:injection, sulfur hexafluoride lipid microsphere, per ml

•

en:injection, paclitaxel, 30 mg administered

•

en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered

•

en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

•

en:everolimus, oral, 0.25 mg

•

en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record

•

en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter

•

en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month

•

en:complete gene sequence analysis; mlh1 gene

•

en:injection, tbo-filgrastim, 5 micrograms

•

en:clinician documented that patient is receiving antiviral treatment for hepatitis c

•

en:injection, testosterone cypionate, up to 100 mg

•

en:lipid profile not performed, reason not given

•

en:injection, vedolizumab, 1 mg administered

•

en:injection, testosterone suspension, up to 50 mg

•

en:aneurysm minor diameter 5.6-6.0 cm for women

•

en:injection, immune globulin (bivigam), 500 mg

•

en:hydroxyzine pamoate, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u.

•

en:automated eeg monitoring

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated

•

en:patient not treated for writing disorder

•

en:lvf testing documented as being performed prior to discharge or in the previous 12 months

•

en:injection, brentuximab vedotin, 1 mg

•

en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given

•

en:most recent hemoglobin (hgb) level > 12.0 g/dl

•

en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient

•

en:angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed for patients with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic fun

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens

•

en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

en:miscellaneous supply or accessory for use with ventricular assist device

•

en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a

•

en:i intend to report the hypertension (htn) measures group

•

en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy

•

en:each additional cervical vertebral body (list separately in addition to code for primary procedure)

•

en:assessment of depression severity not documented, reason not given

•

en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only)

•

en:prescription(s) generated and transmitted via a qualified erx system

•

en:patient not treated for spoken language expression disorder

•

en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:no beta-blocker at discharge

•

en:injection, pertuzumab, 10 mg

•

en:injection, human fibrinogen concentrate, 1 mg administered

•

en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient

•

en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit

•

en:female patients with aneurysm minor diameter >6cm

•

en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.

•

en:diabetes screening test performed

•

en:assessment of depression severity at the initial evaluation

•

en:antiplatelet medication contraindicated

•

en:adenoma(s) or other neoplasm not detected during screening colonoscopy

•

en:skin substitute, endoform dermal template, per square centimeter

•

en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens

•

en:influenza a (h1n1) vaccine, any route of administration

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel

•

en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier

•

en:most current ldl-c >=100mg/dl

•

en:injection, human fibrinogen concentrate, 100 mg

•

en:patient not receiving a first course of anti-tnf therapy

•

en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:antiplatelet medication at discharge

•

en:aneurysm minor diameter >6cm for men

•

en:aneurysm minor diameter <= 5.5 cm

•

en:adenoma(s) or other neoplasm detected during screening colonoscopy

•

en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing

•

en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches

•

en:patient documentation - angina assessed as absent

•

en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)

•

en:patient had a medical visit in the last 6 months

•

en:urine protein test result documented and reviewed

•

en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given

•

en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given

•

en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)

•

en:no anti-lipid treatment at discharge

•

en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index

•

en:aneurysm minor diameter >6cm for women

•

en:injection, zoledronic acid (zometa), 1 mg administered

•

en:injection, tedizolid phosphate, 1 mg

•

en:injectin, epoetin beta, 1 microgram, (for non esrd use)

•

en:grafix core, per square centimeter

•

en:electronic wrist rotator, for utah arm

•

en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given

•

en:beta blocker contraindicated

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf

•

en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient

•

en:12-lead electrocardiogram (ecg) performed

•

en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient

•

en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given

•

en:complete gene sequence analysis for cystic fibrosis genetic testing

•

en:injection, peginesatide, 0.1 mg (for esrd on dialysis)

•

en:clinician documented that patient with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function was not an eligible candidate for angiotensin converting enzyme (ace) inhibi

•

en:dna analysis, fecal, for colorectal cancer screening

•

en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given

•

en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:patient encounter was documented using a pqri qualified ehr or other acceptable systems

•

en:most recent systolic blood pressure < 130 mm hg

•

en:most recent diastolic blood pressure < 80 mm hg

•

en:injection, testosterone enanthate, up to 200 mg administered

•

en:injection, sculptra, 0.1 ml

•

en:i intend to report the back pain measures group

•

en:injection, omacetaxine mepesuccinate, 0.01 mg

•

en:genetic testing for gaucher disease

•

en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:injection, factor viii, fc fusion protein, (recombinant), per i.u.

•

en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes

•

en:genetic testing for canavan disease

•

en:electronic wrist rotator, otto bock or equal

•

en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)

•

en:injection, alemtuzumab, 10 mg administered

•

en:injection, carfilzomib, 1 mg

•

en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg

•

en:most recent ldl-c not under control, results documented and reviewed

•

en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure

•

en:clinician documented that patient did not receive conventional cea

•

en:anticoagulation ordered

•

en:5% dextrose in lactated ringer's, 1000 ml

•

en:hcpcs level ii preferred terms, obsolete

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens

•

en:suicide risk assessed at the initial evaluation

•

en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given

•

en:pneumocystis jiroveci pneumonia prophlaxis prescribed

•

en:aneurysm minor diameter 5.6-6.0 cm

•

en:most recent blood pressure not under control, results documented and reviewed

•

en:i intend to report the epilepsy measures group

•

en:injection, certolizumab pegol, 1 mg

•

en:hemoglobin level measurement not documented, reason not given

•

en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively

•

en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation)

•

en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes

•

en:complete gene sequence analysis for hemochromatosis genetic testing

•

en:anticoagulation was not ordered, reason not given

•

en:anticoagulation not ordered for reasons documented by clinician

•

en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively

•

en:documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate)

•

en:injection, ceftolozane 50 mg and tazobactam 25 mg

•

en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.

•

en:most recent ldl-c under control, results documented and reviewed

•

en:gene expression profiling panel for use in the management of breast cancer treatment

•

en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea

•

en:severity of angina assessed according to level of activity

•

en:score on the writing functional communication measure at discharge was higher than at admission

•

en:score on the spoken language expression functional communication measure at discharge was higher than at admission

•

en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge

•

en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:most recent office visit diastolic blood pressure, <80 mm hg

•

en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:most recent diastolic blood pressure >= 90 mmhg

•

en:injection, belinostat, 10 mg

•

en:most recent blood pressure under control

•

en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater

•

en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:injection, aflibercept, 1 mg administered

•

en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

•

en:injection, interferon beta-1a, 11 mcg for intramuscular use

•

en:injection, ziv-aflibercept, 1 mg

•

en:injection, zoledronic acid (reclast), 1 mg

•

en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)

•

en:ldl-c not performed, reason not given

•

en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:prednisone, oral, per 5 mg

•

en:perphenazine, 8mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility

•

en:most recent systolic blood pressure >= 140 mm hg

•

en:most recent diastolic blood pressure >= 90 mm hg

•

en:ldl-c result not present or not within 12 months prior

•

en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given

•

en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain

•

en:i intend to report the cardiovascular prevention measures group

•

en:injection, pasireotide long acting, 1 mg

•

en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg

•

en:injection, medroxyprogesterone acetate, 50 mg

•

en:injection, elosulfase alfa, 1 mg

•

en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

•

en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries

•

en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given

•

en:injection, oritavancin, 10 mg

•

en:autogenous av fistula received

•

en:male patients with aneurysms minor diameter >6 cm

•

en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined

•

en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission

•

en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals

•

en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms

•

en:rehabilitation services were not ordered, reason not otherwise specified

•

en:pregnancy test (urine or serum) not ordered for reasons documented by clinician

•

en:patient did not have the retina attached after 6 months following only one surgery

•

en:negative pressure ventilator; portable or stationary

•

en:most recent systolic blood pressure >= 140 mmhg

•

en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine

•

en:i intend to report the perioperative care measures group

•

en:injection, peramivir, 1 mg

•

en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)

•

en:documentation of diagnosis of chronic kidney disease

•

en:diabetes screening test not performed, reason not given

•

en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)

•

en:injection, testosterone propionate, up to 100 mg

•

en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)

•

en:most recent systolic blood pressure < 140 mmhg

•

en:most recent office visit diastolic blood pressure, 80 - 89 mm hg

•

en:most recent office visit diastolic blood pressure >=90 mm hg

•

en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge

•

en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:patient documentation - most recent ldl-c < 100 mg/dl

•

en:patient is not eligible for the referral for otologic evaluation measure

•

en:patient not treated for reading disorder

•

en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason

•

en:most recent hemoglobin level <= 12.0 g/dl

•

en:cd4+ cell count or cd4+ cell percentage results documented

•

en:linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment

•

en:i intend to report the ischemic vascular disease (ivd) measures group

•

en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered

•

en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

•

en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter

•

en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period

•

en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet

•

en:compounded drug, not otherwise classified

•

en:complete and appropriate patient data were reported to a qualified clinical database registry

•

en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given

•

en:anti-lipid treatment at discharge

•

en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation

•

en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient

•

thérapie ▷?

•

en:smoking status and exposure to second hand smoke in the home not assessed, reason not given

•

en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer

•

en:score on the motor speech functional communication measure at discharge was higher than at admission

•

en:score on the attention functional communication measure at discharge was higher than at admission

•

en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents

•

en:patient is not eligible for follow-up cta, duplex, or mra (e.g., patient death, failure to return for scheduled follow-up exam, planned follow-up study which will meet numerator criteria has not yet occurred at the time of reporting)

•

en:patients with a positive hepatitis c antibody test

•

en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given

•

en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score

•

en:no antiplatelet medication at discharge

•

en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given

•

en:left ventricular ejection fraction (lvef) was not performed or documented

•

en:insertion of ocular telescope prosthesis including removal of crystalline lens

•

en:injection, obinutuzumab, 10 mg

•

en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered

•

en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg

•

en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial

•

en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:beta-blocker at discharge

•

en:clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incisio

•

aspirine ▷

•

en:oral ▷?

◀

‹

436

en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed

•

en:most recent systolic blood pressure >= 140 mm hg

•

en:positive airway pressure therapy not prescribed

•

en:serum creatinine test not performed, reason not given

•

en:rehabilitation services were not ordered, reason not otherwise specified

•

en:i intend to report the back pain measures group

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens

•

en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)

•

en:severity of angina assessed according to level of activity

•

en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:level of activity and symptoms not assessed

•

en:unlisted procedure, intestine

•

en:urine protein test was not performed, reason not given

•

en:score on the spoken language expression functional communication measure at discharge was higher than at admission

•

en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)

•

en:no anti-lipid treatment at discharge

•

en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase

•

en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:antiplatelet medication contraindicated

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel

•

en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)

•

en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes

•

en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)

•

en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain

•

en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries

•

en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given

•

en:patient had a medical visit in the last 6 months

•

en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine

•

en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score

•

en:score on the attention functional communication measure at discharge was higher than at admission

•

en:score on the motor speech functional communication measure at discharge was higher than at admission

•

en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission

•

en:pregnancy test (urine or serum) was not ordered, reason not specified

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase

•

en:no documentation of disease type, anatomic location, and activity, reason not given

•

en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason

•

en:patient not treated for memory disorder

•

en:diabetes screening test not performed, reason not given

•

en:electronic wrist rotator, otto bock or equal

•

en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer

•

en:injection, taliglucerase alfa, 10 units

•

en:fluocinolone acetonide, intravitreal implant

•

en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet

•

en:genetic testing for gaucher disease

•

en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:i intend to report the hypertension (htn) measures group

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:injection, ziv-aflibercept, 1 mg

•

en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given

•

en:i intend to report the perioperative care measures group

•

en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter

•

en:prednisone, oral, per 5 mg

•

en:netupitant 300 mg and palonosetron 0.5 mg

•

en:injection, testosterone cypionate, up to 100 mg

•

en:patient documentation - angina assessed as present

•

en:injection, belinostat, 10 mg

•

en:patient not treated for motor speech disorder

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed

•

en:injection, peginesatide, 0.1 mg (for esrd on dialysis)

•

en:hcpcs level ii preferred terms, obsolete

•

en:beta-blocker at discharge

•

en:vacuum drainage bottle and tubing for use with implanted catheter

•

en:compounded drug, not otherwise classified

•

en:injection, testosterone enanthate, up to 200 mg administered

•

en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)

•

en:ldl-c not performed, reason not given

•

en:injection, sulfur hexafluoride lipid microsphere, per ml

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given

•

en:injection, testosterone enanthate, up to 100 mg administered

•

en:prostate cancer antigen 3 (pca3) testing

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery

•

en:most recent blood pressure under control

•

en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month

•

en:complete gene sequence analysis; mlh1 gene

•

en:patient documentation - angina assessed as absent

•

en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents

•

en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression

•

en:most recent ldl-c under control, results documented and reviewed

•

en:prescription(s) generated and transmitted via a qualified erx system

•

en:abdominal aortic aneurysm is not infarenal

•

en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches

•

en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient

•

en:injection, factor viii, fc fusion protein, (recombinant), per i.u.

•

en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter

•

en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission

•

en:counseling for diet and physical activity not performed, reason not given

•

en:grafix prime, per square centimeter

•

en:lipid profile not performed, reason not given

•

en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given

•

en:patch closure used for patient undergoing conventional cea

•

en:patient not treated for spoken language expression disorder

•

en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis performed

•

en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:documentation of diagnosis of chronic kidney disease

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed

•

en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:counseling for diet and physical activity performed

•

en:injection, medroxyprogesterone acetate, 50 mg

•

en:most recent ldl-c not under control, results documented and reviewed

•

en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.

•

en:patient not treated for writing disorder

•

en:hemoglobin level measurement not documented, reason not given

•

en:injection, filgrastim (g-csf), 480 mcg

•

en:injection, testosterone suspension, up to 50 mg

•

en:intraoperative radiation therapy (single administration)

•

en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function

•

en:most recent systolic blood pressure 130 to 139 mm hg

•

en:injection, aflibercept, 1 mg administered

•

en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given

•

en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)

•

en:aneurysm minor diameter >6cm for men

•

en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c

•

en:injection, carfilzomib, 1 mg

•

en:injection, propofol, 10 mg

•

en:injection, tbo-filgrastim, 5 micrograms

•

en:injection, testosterone undecanoate, 1 mg

•

en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period

•

en:injection, nivolumab, 1 mg

•

en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory

•

en:injection, brentuximab vedotin, 1 mg

•

en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)

•

en:assessed level of activity and symptoms

•

en:aneurysm minor diameter >6cm for women

•

en:patient not treated for attention disorder

•

en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given

•

en:patient receiving antiviral treatment for hepatitis c documented

•

en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit

•

en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given

•

en:ldl-c was not performed

•

en:levonorgestrel 52mg intrauterine system

•

en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:suicide risk not assessed at the initial evaluation, reason not given

•

en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg

•

en:injection, alemtuzumab, 10 mg administered

•

en:ldl value >= 100

•

en:12-lead electrocardiogram (ecg) performed

•

en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient

•

en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given

•

en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg

•

en:injection, pembrolizumab, 1 mg

•

en:i intend to report the cardiovascular prevention measures group

•

en:ldl value < 100

•

en:most recent systolic blood pressure < 140 mmhg

•

en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure

•

en:most recent office visit diastolic blood pressure, <80 mm hg

•

en:dna analysis, fecal, for colorectal cancer screening

•

en:injection, interferon beta-1a, 11 mcg for intramuscular use

•

en:most current ldl-c >=100mg/dl

•

en:most recent diastolic blood pressure < 80 mm hg

•

en:most recent office visit systolic blood pressure >=140 mm hg

•

en:patch closure not used for patient undergoing conventional cea, reason not specified

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens

•

en:injection, elosulfase alfa, 1 mg

•

en:injection, factor viii fc fusion protein(recombinant), per iu

•

en:i intend to report the community-acquired pneumonia (cap) measures group

•

en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater

•

en:suicide risk assessed at the initial evaluation

•

en:electronic wrist rotator, for utah arm

•

en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg

•

en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy

•

en:injection, sculptra, 0.1 ml

•

en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:anti-lipid treatment at discharge

•

en:patient not treated for reading disorder

•

en:complete gene sequence analysis; brca2 gene

•

en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea

•

en:pneumocystis jiroveci pneumonia prophlaxis prescribed

•

en:cd4+ cell count or cd4+ cell percentage results documented

•

en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility

•

en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge

•

en:injection, immune globulin (bivigam), 500 mg

•

en:urine protein test result documented and reviewed

•

en:5% dextrose in lactated ringer's, 1000 ml

•

en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient

•

en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient

•

en:aneurysm minor diameter <= 5.5 cm for women

•

en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)

•

en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing

•

en:most recent systolic blood pressure < 130 mm hg

•

en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg

•

en:injection, ibuprofen, 100 mg

•

en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg

•

en:injection, obinutuzumab, 10 mg

•

en:injection, zoledronic acid (reclast), 1 mg

•

en:insertion of ocular telescope prosthesis including removal of crystalline lens

•

en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session

•

en:score on the memory functional communication measure at discharge was higher than at admission

•

en:hemodialysis treatment performed exactly three times per week for > 90 days

•

en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units

•

en:mandibular orthopedic repositioning device, each

•

en:genetic testing for detection of mutations in the presenilin - 1 gene

•

en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:female patients with aneurysm minor diameter >6cm

•

en:injection, ferric carboxymaltose, 1 mg

•

en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge

•

en:most recent office visit diastolic blood pressure, 80 - 89 mm hg

•

en:genetic testing for canavan disease

•

en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.

•

en:score on the reading functional communication measure at discharge was higher than at admission

•

en:aneurysm minor diameter <= 6 cm for men

•

en:injection, human fibrinogen concentrate, 100 mg

•

en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:anticoagulation not ordered for reasons documented by clinician

•

en:assessment of depression severity at the initial evaluation

•

en:injection, pertuzumab, 10 mg

•

en:injection, zoledronic acid (zometa), 1 mg administered

•

en:miscellaneous supply or accessory for use with ventricular assist device

•

en:score on the writing functional communication measure at discharge was higher than at admission

•

en:injection, tedizolid phosphate, 1 mg

•

en:complete gene sequence analysis; brca1 gene

•

en:patient did not have a medical visit in the last 6 months

•

en:patient is not eligible for the referral for otologic evaluation measure

•

en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given

•

en:type, anatomic location, and activity all documented

•

en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient

•

en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure

•

en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial

•

en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:hemodialysis treatment performed less than three times per week or greater than three times per week

•

en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

•

en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater

•

en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered

•

en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:injection, epoetin beta, 1 microgram, (for esrd on dialysis)

•

en:injection, ramucirumab, 5 mg administered

•

en:pregnancy test (urine or serum) not ordered for reasons documented by clinician

•

en:injection, ceftolozane 50 mg and tazobactam 25 mg

•

en:i intend to report the epilepsy measures group

•

en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a

•

en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given

•

en:injection, blinatumomab, 1 mcg

•

en:patients with a positive hepatitis c antibody test

•

en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer

•

en:injection, ocriplasmin, 0.125 mg

•

en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:injection, morphine sulfate, 100mg

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge

•

en:implanted pleural catheter, each

•

en:anticoagulation was not ordered, reason not given

•

en:circulating tumor cell test

•

en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia

•

en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals

•

en:injection, isavuconazonium sulfate, 1 mg

•

en:each additional cervical vertebral body (list separately in addition to code for primary procedure)

•

en:gene expression profiling panel for use in the management of breast cancer treatment

•

en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy

•

en:patient did not have the retina attached after 6 months following only one surgery

•

en:injection, testosterone propionate, up to 100 mg

•

en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month)

•

en:patient did not achieve flat retinas six months post surgery

•

en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only)

•

en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient

•

en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given

•

en:injection, interferon beta-1a, 11 mcg for subcutaneous use

•

en:pregnancy test (urine or serum) ordered

•

en:injection, ado-trastuzumab emtansine, 1 mg

•

en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron

•

en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively

•

en:lvf testing documented as being performed prior to discharge or in the previous 12 months

•

en:most recent diastolic blood pressure 80 - 89 mm hg

•

en:no beta-blocker at discharge

•

en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index

•

en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge

•

en:most recent office visit systolic blood pressure, 130 to 139 mm hg

•

en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical

•

en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge

•

en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation

•

en:patient not receiving a first course of anti-tnf therapy

•

en:patient encounter was documented using a pqri qualified ehr or other acceptable systems

•

en:no documentation of blood pressure measurement, reason not given

•

en:most recent systolic blood pressure >= 140 mmhg

•

en:no antiplatelet medication at discharge

•

en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function

•

en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation)

•

en:anti-lipid treatment contraindicated

•

en:aneurysm minor diameter 5.6-6.0 cm

•

en:clinician documented that patient was not an eligible candidate for autogenous av fistula

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated

•

en:injection, vedolizumab, 1 mg administered

•

en:ldl-c result not present or not within 12 months prior

•

en:most recent diastolic blood pressure < 90 mmhg

•

en:most recent office visit diastolic blood pressure >=90 mm hg

•

en:skin substitute, endoform dermal template, per square centimeter

•

en:injection, omacetaxine mepesuccinate, 0.01 mg

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf

•

en:anoscopy; with directed submucosal injection(s), any substance

•

en:anticoagulation ordered

•

en:clinician documented that patient did not receive conventional cea

•

en:complete gene sequence analysis for cystic fibrosis genetic testing

•

en:most recent ldl-c >= 100 mg/dl

•

en:injection, paclitaxel, 30 mg administered

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens

•

en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml

•

en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg

•

en:male patients with aneurysms minor diameter >6 cm

•

en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge

•

en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given

•

en:12-lead electrocardiogram (ecg) not performed, reason not given

•

en:serum creatinine test result documented and reviewed

•

en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family)

•

en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke

•

en:aneurysm minor diameter 5.6-6.0 cm for women

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)

•

en:diabetes screening test performed

•

en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation)

•

en:eligible professional does not have prescribing privileges

•

en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient

•

en:injectin, epoetin beta, 1 microgram, (for non esrd use)

•

en:injection, certolizumab pegol, 1 mg

•

en:injection, oritavancin, 10 mg

•

en:injection, zoledronic acid, not otherwise specified, 1mg

•

en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg)

•

en:most recent blood pressure not under control, results documented and reviewed

•

en:injection, belatacept, 1 mg

•

en:most recent diastolic blood pressure >= 90 mmhg

•

en:clinician documented that patient is receiving antiviral treatment for hepatitis c

•

en:female patients with aneurysm minor diameter 5.6-6.0 cm

•

en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

•

en:influenza a (h1n1) vaccine, any route of administration

•

en:patient not treated for swallowing disorder

•

en:most recent hemoglobin (hgb) level > 12.0 g/dl

•

en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given

•

en:patient not treated for spoken language comprehension disorder

•

en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible

•

en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms

•

en:adenoma(s) or other neoplasm detected during screening colonoscopy

•

en:capsaicin 8% patch, per 10 square centimeters

•

en:severity of angina not assessed according to level of activity

•

en:injection, pasireotide long acting, 1 mg

•

en:automated eeg monitoring

•

en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment)

•

en:epifix, per square centimeter

•

en:injection, human fibrinogen concentrate, 1 mg administered

•

en:complete gene sequence analysis; msh2 gene

•

en:injection, siltuximab, 10 mg

•

en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge

•

en:kras mutation analysis

•

en:most recent office visit systolic blood pressure <130 mm hg

•

en:patient documentation - most recent ldl-c < 100 mg/dl

•

en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered

•

en:blood pressure measurement not documented, reason not given

•

en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined

•

en:injection, dalbavancin, 10 mg administered

•

en:left ventricular ejection fraction (lvef) was not performed or documented

•

en:injection, peramivir, 1 mg

•

en:injection, testosterone cypionate, 1 cc, 200 mg

•

en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

en:smoking status and exposure to second hand smoke in the home not assessed, reason not given

•

en:aneurysm minor diameter <= 5.5 cm

•

en:autogenous av fistula received

•

en:injection, aflibercept, 2 mg vial

•

en:tissue marker (implantable)

•

en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u.

•

en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given

•

en:beta blocker contraindicated

•

en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

•

en:complete and appropriate patient data were reported to a qualified clinical database registry

•

en:aneurysm minor diameter <= 5.5 cm for men

•

en:most current ldl-c <100mg/dl

•

en:most recent hemoglobin level <= 12.0 g/dl

•

en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge

•

en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function

•

en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation

•

en:most recent diastolic blood pressure >= 90 mm hg

•

en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)

•

en:cd4+ cell count or percentage not documented as performed, reason not given

•

en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively

•

en:everolimus, oral, 0.25 mg

•

en:negative pressure ventilator; portable or stationary

•

en:injection, filgrastim (g-csf), 300 mcg

•

en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel

•

en:antiplatelet medication at discharge

•

en:assessment of depression severity not documented, reason not given

•

en:injection, alemtuzumab, 1 mg

•

en:aneurysm minor diameter 5.6-6.0 cm for men

•

en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing

•

en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given

•

en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge

•

en:i intend to report the ischemic vascular disease (ivd) measures group

•

en:grafix core, per square centimeter

•

en:genetic testing for tay-sachs disease

•

en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

•

en:complete gene sequence analysis for hemochromatosis genetic testing

•

en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given

•

en:adenoma(s) or other neoplasm not detected during screening colonoscopy

•

thérapie ▷?

◀

Génériques

[F] [H]

›

en:finding ▷?

•

en:oral ▷?

• Mathieu Lafourcade • LIRMM (données libres en Creative Commons) •

• This page link : https://www.jeuxdemots.org/diko.php?gotermid=8087735 • caches: c1=90 c2=1138 c3=953

....

+/-

♥

po

la

ti

le

as

ku

co

lo

to

ta

ta

xe

po

li

?!

!?

[Vider le cache]